Important Information for Pacira BioSciences, Inc. Securities Holders: Rosen Law Firm Announces Deadline Reminder for Class Action Lawsuit
New York, NY – March 11, 2025
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023, and August 8, 2024, both dates inclusive (the “Class Period”), of the important March 14, 2025 lead plaintiff deadline. Investors who purchased Pacira securities during the Class Period are encouraged to contact the firm before this deadline.
What is a Class Action Lawsuit?
A class action is a type of lawsuit where a group of individuals or entities join together to bring a claim against a defendant. In a securities class action, the plaintiffs allege that the defendant made false or misleading statements or failed to disclose important information, causing the securities to be artificially inflated or deflated. Class action lawsuits allow investors to recover their losses without the need for individual lawsuits, which can be time-consuming and expensive.
Why is Rosen Law Firm involved?
Rosen Law Firm is a leading law firm in securities class actions. The firm has a proven track record of recovering significant damages for investors. The firm’s team of experienced attorneys has a deep understanding of the securities industry and the laws that govern it. If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What Happened to Pacira?
On August 9, 2024, Pacira announced that its Exparel product, a non-opioid pain management system, failed to meet the primary and secondary endpoints in a late-stage clinical trial. The news caused Pacira’s stock price to drop significantly. The securities class action alleges that the company failed to disclose this information to investors, despite having knowledge of the trial results before the public announcement.
How Does this Affect Me?
If you purchased Pacira securities during the Class Period and suffered losses as a result of the August 9, 2024 announcement, you may be entitled to compensation. The amount of damages you may recover will depend on the specifics of your case and the size of your investment. It is important to contact a securities attorney as soon as possible to discuss your options and protect your rights.
How Does this Affect the World?
The Pacira class action is an important reminder of the need for transparency and full disclosure in the securities industry. When companies fail to disclose important information, investors can suffer significant losses. The case also highlights the importance of working with experienced securities attorneys to protect your rights and recover your losses.
Conclusion
If you purchased Pacira securities between August 2, 2023, and August 8, 2024, and suffered losses as a result of the August 9, 2024 announcement, you may be entitled to compensation. Contact Rosen Law Firm before the March 14, 2025 lead plaintiff deadline to discuss your options and protect your rights. The firm’s team of experienced securities attorneys has a proven track record of recovering significant damages for investors.
- Rosen Law Firm reminds Pacira securities holders of the March 14, 2025 lead plaintiff deadline.
- Investors who purchased Pacira securities during the Class Period may be entitled to compensation.
- The case involves Pacira’s failed Exparel product clinical trial.
- Contact Rosen Law Firm for a free consultation to discuss your options.
